The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Psychopharmacologic Treatment of Schizophrenia
Open accessAbstract
Antipsychotic (neuroleptic) medications continue to be a critical component in the treatment of schizophrenia. Despite numerous advances in brain imaging, genetics, and neurochemistry, the pharmacologic agents routinely used to treat schizophrenia have not changed markedly over the last 30 years. The introduction of clozapine, however, represents an important step in drug development and has stimulated renewed activity in this area. In addition, its novel effects have had a heuristic value in efforts to better understand neuropharmacologic mechanisms. While we await further advances in treatment development, we are benefiting from clinical research focusing on improving our ability to use available pharmacotherapy in the most effective and least toxic manner. Recent studies reemphasize the potential value of using the minimum effective dosage for acute treatment (e.g., 10-15 mg/day of oral haloperidol) and provide needed data on the benefits and risks of long-term dosage reduction strategies (i.e., continuous low-dose or targeted/intermittent treatment).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
Clozapine for the Treatment-Resistant Schizophrenic: A Double-blind Comparison With Chlorpromazine
Kane, J. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800330013001 · Cited by 4,156
Self-citationComprehensive Textbook of Psychiatry
Freedman, A. M., & Kaplan, H. I. (1967) · The American Journal of the Medical Sciences · doi:10.1097/00000441-196712000-00052 · Cited by 3,799
Sokoloff, P., Giros, B., Martres, M.-P., Bouthenet, M.-L., & Schwartz, J.-C. (1990) · Nature · doi:10.1038/347146a0 · Cited by 2,609
Dopamine Receptor Binding Predicts Clinical and Pharmacological Potencies of Antischizophrenic Drugs
Creese, I., Burt, D. R., & Snyder, S. H. (1976) · Science · doi:10.1126/science.3854 · Cited by 2,220
Van Tol, H. H. M., Bunzow, J. R., Guan, H.-C., Sunahara, R. K., Seeman, P., Niznik, H. B., & Civelli, O. (1991) · Nature · doi:10.1038/350610a0 · Cited by 2,014
Molecular pathology of schizophrenia: more than one disease process?
Crow, T. J. (1980) · BMJ · doi:10.1136/bmj.280.6207.66 · Cited by 1,856
Significance of Neuroleptic Dose and Plasma Level in the Pharmacological Treatment of Psychoses
Baldessarini, R. J. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800250095013 · Cited by 545
(1980) · American Journal of Psychiatry · doi:10.1176/ajp.137.7.801 · Cited by 455
Overview: maintenance therapy in psychiatry: I. Schizophrenia
(1975) · American Journal of Psychiatry · doi:10.1176/ajp.132.12.1237 · Cited by 410
Kane, J. M. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.1.133 · Cited by 323
Self-citationProvocation of Schizophrenic Symptoms by Intravenous Administration of Methylphenidate
Janowsky, D. S. (1973) · Archives of General Psychiatry · doi:10.1001/archpsyc.1973.01750320023004 · Cited by 310
The Effects of Clozapine on Tardive Dyskinesia
Lieberman, J. A., Saltz, B. L., Johns, C. A., Pollack, S., Borenstein, M., & Kane, J. (1991) · British Journal of Psychiatry · doi:10.1192/bjp.158.4.503 · Cited by 302
Self-citationImportant Issues in the Drug Treatment of Schizophrenia
Davis, J. M., Schaffer, C. B., Killian, G. A., Kinard, C., & Chan, C. (1980) · Schizophrenia Bulletin · doi:10.1093/schbul/6.1.70 · Cited by 284
Kane, J. M. (1983) · Archives of General Psychiatry · doi:10.1001/archpsyc.1983.01790070083010 · Cited by 273
Self-citationLindström, L. H. (1988) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1988.tb05164.x · Cited by 246
Low- and Conventional-Dose Maintenance Therapy With Fluphenazine Decanoate: Two-Year Outcome
Marder, S. R. (1987) · Archives of General Psychiatry · doi:10.1001/archpsyc.1987.01800180028005 · Cited by 245
Self-citationHogarty, G. E. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800330021002 · Cited by 239
Clozapine: guidelines for clinical management.
Lieberman, J. A., Kane, J. M., & Johns, C. A. (1989) · PubMed · Cited by 226
Self-citationHLA-B38, DR4, DQw3 and Clozapine-Induced Agranulocytosis in Jewish Patients With Schizophrenia
Lieberman, J. A. (1990) · Archives of General Psychiatry · doi:10.1001/archpsyc.1990.01810220061007 · Cited by 207
Integrating incidence and prevalence of tardive dyskinesia.
Kane, J. M., Woerner, M. G., Borenstein, M., Wegner, J. T., & Lieberman, J. A. (1986) · PubMed · Cited by 207
Self-citationA Controlled Dose Comparison of Haloperidol in Newly Admitted Schizophrenic Patients
Van Putten, T. (1990) · Archives of General Psychiatry · doi:10.1001/archpsyc.1990.01810200062009 · Cited by 188
Costs and Benefits of Two Doses of Fluphenazine
Marder, S. R. (1984) · Archives of General Psychiatry · doi:10.1001/archpsyc.1983.01790220015002 · Cited by 182
Self-citationIdänpään-Heikkilä, J., Alhava, E., Olkinuora, M., & Palva, I. (1975) · The Lancet · doi:10.1016/s0140-6736(75)90206-8 · Cited by 181
When Symptoms Persist: Choosing Among Alternative Somatic Treatments for Schizophrenia
Christison, G. W., Kirch, D. G., & Wyatt, R. J. (1991) · Schizophrenia Bulletin · doi:10.1093/schbul/17.2.217 · Cited by 176
Negative and Deficit Symptoms in Schizophrenia Do Respond to Neuroleptics
Goldberg, S. C. (1985) · Schizophrenia Bulletin · doi:10.1093/schbul/11.3.453 · Cited by 174
Haloperidol plasma levels and clinical response: a therapeutic window relationship
Van Putten, T., Marder, S. R., Mintz, J., & Poland, R. E. (1992) · American Journal of Psychiatry · doi:10.1176/ajp.149.4.500 · Cited by 158
Self-citationAdjunctive Imipramine in the Treatment of Postpsychotic Depression
Siris, S. G. (1987) · Archives of General Psychiatry · doi:10.1001/archpsyc.1987.01800180043008 · Cited by 149
Responses to apomorphine, amphetamine, and neuroleptics in schizophrenic subjects
Angrist, B., Rotrosen, J., & Gershon, S. (1980) · Psychopharmacology · doi:10.1007/bf00427592 · Cited by 140
Early Intervention, Time-limited, Targeted Pharmacotherapy of Schizophrenia
Carpenter, W. T., & Heinrichs, D. W. (1983) · Schizophrenia Bulletin · doi:10.1093/schbul/9.4.533 · Cited by 138
Rapid Treatment of Acute Psychotic Symptoms With High- and Low-Dose Haloperidol
Neborsky, R. J. (1981) · Archives of General Psychiatry · doi:10.1001/archpsyc.1981.01780270081011 · Cited by 134
A depot neuroleptic withdrawal study
Wistedt, B., J�rgensen, A., & Wiles, D. (1982) · Psychopharmacology · doi:10.1007/bf00433729 · Cited by 134
Dissimilar dosing with high-potency and low-potency neuroleptics
Baldessarini, R. J., Katz, B., & Cotton, P. G. (1984) · American Journal of Psychiatry · doi:10.1176/ajp.141.6.748 · Cited by 131
Treatment of Secondary Depression in Schizophrenia
Prusoff, B. A. (1979) · Archives of General Psychiatry · doi:10.1001/archpsyc.1979.01780050079010 · Cited by 130
Neuroleptic affinities for human brain receptors and their use in predicting adverse effects.
Richelson, E. (1984) · PubMed · Cited by 127
Clozapine-induced agranulocytosis: non-cross-reactivity with other psychotropic drugs.
Lieberman, J. A., Johns, C. A., Kane, J. M., Rai, K., Pisciotta, A. V., Saltz, B. L., & Howard, A. (1988) · PubMed · Cited by 125
Self-citationDrug discontinuation among long term, successfully maintained schizophrenic outpatients.
Ge, H., Ulrich, R. F., Mussare, F., & Aristigueta, N. (1976) · PubMed · Cited by 118
Prediction of Relapse in Schizophrenia
Lieberman, J. A. (1987) · Archives of General Psychiatry · doi:10.1001/archpsyc.1987.01800190013002 · Cited by 114
A depot neuroleptic withdrawal study
Wistedt, B. (1981) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1981.tb00761.x · Cited by 113
Haloperidol Blood Levels and Clinical Effects
Volavka, J. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820050018002 · Cited by 112
Dosage of Haloperidol for Schizophrenia
Rifkin, A. E., Doddi, S. R., Karajgi, B. M., Borenstein, M., & Wachspress, M. (1991) · Archives of General Psychiatry · doi:10.1001/archpsyc.1991.01810260074011 · Cited by 108
Fluphenazine Dose, Clinical Response, and Extrapyramidal Symptoms During Acute Treatment
Levinson, D. F. (1990) · Archives of General Psychiatry · doi:10.1001/archpsyc.1990.01810200069010 · Cited by 97
Atypical neuroleptics: role of multiple receptors, endogenous dopamine, and receptor linkage
Seeman, P. M. (1990) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1990.tb05280.x · Cited by 95
Psychosocial treatment of schizophrenia
Melle, I. S., & Friis, S. (1991) · Nordic Journal of Psychiatry · doi:10.3109/08039489109103273 · Cited by 89
Griffith, R., & Saameli, K. (1975) · The Lancet · doi:10.1016/s0140-6736(75)90135-x · Cited by 89
Schizophrenics Fully Remitted on Neuroleptics for 3–5 years—To Stop or Continue Drugs?
Cheung, H. K. (1981) · The British Journal of Psychiatry · doi:10.1192/bjp.138.6.490 · Cited by 82
Clinical response and plasma haloperidol levels in schizophrenia
Mavroidis, M. L., Kanter, D. R., Hirschowitz, J., & Garver, D. L. (1983) · Psychopharmacology · doi:10.1007/bf00427577 · Cited by 82
Clozapine: Plasma levels and prolactin response
Kane, J. M., Cooper, T. B., Sachar, E. J., Halpern, F. S., & Bailine, S. H. (1981) · Psychopharmacology · doi:10.1007/bf00429215 · Cited by 81
Self-citationFurther Observations on the Duration of Depot Neuroleptic Maintenance Therapy in Schizophrenia
Johnson, D. A. W. (1979) · The British Journal of Psychiatry · doi:10.1192/bjp.135.6.524 · Cited by 66
Depot neuroleptics: a comparative review of standard, intermediate, and low-dose regimens.
Kane, J. M., Woerner, M. G., & Sarantakos, S. (1986) · PubMed · Cited by 62
Self-citationDencker, S. J., Lepp, M., & Malm, U. (1980) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1980.tb07084.x · Cited by 57
Marder, S. R., Midha, K. K., Putten, T. V., Aravagiri, M., Hawes, E. M., Hubbard, J. W., McKay, G., & Mintz, J. (1991) · The British Journal of Psychiatry · doi:10.1192/bjp.158.5.658 · Cited by 56
Self-citationHj, H. (1961) · PubMed · Cited by 55
Response to clozapine in chronic psychotic patients.
Rr, O., Beake, B., Marby, D. W., et al. (1989) · PubMed · Cited by 52
Recent Advances in Schizophrenia
Kales, A., Stefanis, C. N., & Talbott, J. A. (1990) · International perspectives series : psychiatry, psychology, and neurosciences · doi:10.1007/978-1-4612-3248-3 · Cited by 49
Drug Maintenance Strategies in Schizophrenia
SLAWSKY, R. (1986) · American Journal of Psychiatry · doi:10.1176/ajp.143.1.101-a · Cited by 43
Pimozide versus Haloperidol in Acute Schizophrenia. A Double Blind Controlled Study
Haas, S., & Beckmann, H. (1982) · Pharmacopsychiatry · doi:10.1055/s-2007-1019512 · Cited by 41
Clozapine: Mechanism of Action in Relation to its Clinical Advantages
Meltzer, H. Y. (1990) · International perspectives series : psychiatry, psychology, and neurosciences · doi:10.1007/978-1-4612-3248-3_11 · Cited by 35
The use of monoamine oxidase inhibitors in schizophrenia.
Brenner, R., & Shopsin, B. (1980) · PubMed · Cited by 29
Smith, R. C., Baumgartner, R., Shvartsburd, A., Ravichandran, G., Vroulis, G., & Mauldin, M. (1985) · Psychopharmacology · doi:10.1007/bf00429663 · Cited by 27
Targeted treatment of depression-like symptoms in schizophrenia.
Sg, S., Adan, F., Cohen, M. A., Mandeli, J., Aronson, A. C., & Fasano-Dube, B. (1987) · PubMed · Cited by 27
Thoughts on the Treatment of Schizophrenia
Carpenter, W. T. (1986) · Schizophrenia Bulletin · doi:10.1093/schbul/12.4.527 · Cited by 26
Cited by
Lehman, A. F., Steinwachs, D. M., & The Co-Investigators of the PORT Project (1998) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a033302 · Cited by 910
Mueser, K. T., & McGurk, S. R. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16458-1 · Cited by 876
Metabolomics: A Global Biochemical Approach to Drug Response and Disease
Kaddurah-Daouk, R., Kristal, B. S., & Weinshilboum, R. M. (2008) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.48.113006.094715 · Cited by 670
Hasan, A., Falkai, P., Wobrock, T., Lieberman, J., Glenthoj, B., Gattaz, W. F., Thibaut, F., Möller, H.-J., & the Wfsbp Task Force on Treatment Guidelines for Schizophrenia (2012) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2012.696143 · Cited by 637
State of the Science on Psychosocial Interventions for Ethnic Minorities
Miranda, J., Bernal, G., Lau, A., Kohn, L., Hwang, W.-C., & LaFromboise, T. (2005) · Annual Review of Clinical Psychology · doi:10.1146/annurev.clinpsy.1.102803.143822 · Cited by 534
Metadata
- Authors
- Kane, J. M., & Marder, S. R.
- Venue
- Schizophrenia Bulletin
- Publisher
- Oxford University Press (OUP)
- Published
- 1993-01-01
- Volume
- 19
- Issue
- 2
- Pages
- 287-302
- ISSN
- 0586-7614 (ISSN-L)
- 1745-1701
- OpenAlex
- W2057923287
- Cited by
- 273
- References
- 62
- FWCI
- 12.64
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.